Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions

Transfusion

Volumn 53, Issue 2, 2013, Pages 412-418

  Klingemann, Hans ^a   Grodman, Carrie ^b   Cutler, Elliott ^b   Duque, Marvin ^b   Kadidlo, Diane ^b   Klein, Andreas K ^b   Sprague, Kellie A ^b   Miller, Kenneth B ^b   Comenzo, Raymond L ^b   Kewalramani, Tarun ^b   Yu, Neng ^b   Van Etten, Richard A ^b   McKenna, David H ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CELL VIABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; DONOR NATURAL KILLER CELL ENRICHED MONONUCLEAR CELL INFUSION; FEASIBILITY STUDY; FEMALE; FLUSHING; FOLLICULAR LYMPHOMA; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAPLOIDY; HUMAN; IMMUNOMAGNETIC SEPARATION; IMMUNOTHERAPY; LARGE CELL LYMPHOMA; LEUKAPHERESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MANTLE CELL LYMPHOMA; MONONUCLEAR CELL; MYALGIA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PATIENT SAFETY; PRURITUS; RIGOR; STEADY STATE;

ADULT; AGED; BLOOD DONORS; FAMILY; FEASIBILITY STUDIES; FEMALE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; INFUSIONS, INTRAVENOUS; KILLER CELLS, NATURAL; LEUKAPHERESIS; MALE; MIDDLE AGED; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873449050     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03764.x     Document Type: Article

References (34)

1. Pasquini MC, Wang Z,. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides. 2011. [cited 2012 Jun 7]. Available from: URL: http://www.cibmtr.org
2. Dean M, Fojo T, Bates S,. Tumor stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-84.
3. Rich JN,. Cancer stem cells in radiation resistance. Cancer Res 2007; 67: 8980-4.
4. Eyler CE, Rich JN,. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26: 2839-45.
5. Malmberg K-J,. Effective Immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 2004; 53: 879-92.
6. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B,. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-62.
7. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ,. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767-76.
8. Ljunggren HG, Karre K,. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today 1990; 11: 237-44.
9. Lanier LL,. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495-502.
10. Méndez R, Rodríguez T, Del Campo A, Monge E, Maleno I, Aptsiauri N, Jimenez P, Pedrinaci S, Pawalec G, Ruiz-Cabello F, Garrido F,. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol Immunother 2008; 57: 719-29.
11. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F,. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004; 53: 904-10.
12. Verheyden S, Demanet C,. NK cell receptors and their ligands in leukemia. Leukemia 2008; 22: 249-57.
13. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale M,. NK cells and cancer. J Immunol 2007; 178: 4011-6.
14. Ruggeri L, Campanni M, Casucci M, Volpi I, Tosti A, Perruccio K, Urbani E, Negrin RS, Martelli MF, Velardi A,. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94: 333-9.
15. Ruggeri L, Mancusi A, Capanni M, Urbani E, Carotti A, Aloisi T, Stern M, Pende D, Perruccio K, Burchielli E, Topini F, Bianchi E, Aversa F, Martelli MF, Velardi A,. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007; 110: 433-40.
16. Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caliguri MA, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch PE, Anasetti C, Kamani N, Miller JS, Davies SM,; KIR Study Group, Center for International Blood and Marrow Transplantation Research. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the Center for International Blood and Marrow Transplant Research, the European Blood and Marrow Transplant Registry, and the Dutch Registry. Biol Blood Marrow Transplant 2006; 12: 876-84.
17. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A,. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood 2011; 117: 764-71.
18. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachenberg E, Partham P, Miller JS,. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411-9.
19. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQuenn KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ,. Missing KIR-ligands is associated with less relapse and increased graftversus host disease (GVHD) following unrelated donor allogeneic HCT. Blood 2007; 109: 5058-61.
20. Godal R, Bachanova V, Gleason M, McCullar V, Yun GH, Cooley S, Verneris MR, McGlave PB, Miller JS,. Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade. Biol Blood Marrow Transplant 2010; 16: 612-21.
21. McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, Dewaard R, McGlave PB, Weisdorf DJ, Wagner JE, McCullough J, Miller JS,. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single institution experience. Transfusion 2007; 47: 520-8.
22. Boissel L, Tuncer HH, Betancur M, Wolfberg A, Klingemann H,. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol Blood Marrow Transplant 2008; 14: 1031-8.
23. National Cancer Institute. Cancer therapy evaluation program, common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS. 2003. [cited 2012 Jun 7]. Available from: URL: http://ctep.cancer.gov
24. Koepsell S, Kadidlo D, Fautsch S, McCullough J, Klingemann H, Wagner J, Miller J, McKenna D,. Successful "in-flight"activation during long-distance shipping. Transfusion 2013; 53: 398-403.
25. Hummon D, Zantek ND, Sumstad D, Miller JS, McKenna DH,. Transfusion associated graft versus host disease: a perspective from a cell therapy laboratory. Transfusion 2009; 49: 1018-9.
26. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna DH, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB,. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-7.
27. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H,. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10: 625-32.
28. Lundqvist A, McCoy JP, Samsel L, Childs R,. Reduction of GvHD and enhanced antitumor effects after adoptive infusion of alloreactive ly49 mismatched NK cells from MHC matched donors. Blood 2007; 109: 3603-6.
29. Rizzieri DA, Storms R, Chen DF, Long G, Yang Y, Nikcevich DA, Gasparetto C, Horwitz M, Chute J, Sullivan K, Hennig T, Misra D, Apple C, Baker M, Morris A, Green PG, Hasselblad V, Chao NJ,. Natural killer cell-enriched donor lymphocyte infusion from 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 1107-14.
30. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y,. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006; 176: 1582-7.
31. Rosenberg SA, Restifo N, Yang J, Morgan R, Dudley M,. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Rev Cancer 2008; 8: 299-308.
32. Klebanoff CA, Khong HT, Antony PA, 579 Palmer DC, Restifo NP,. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor Immunotherapy. Trends Immunol 2005; 26: 111-7.
33. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA,. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23: 346-57.
34. Reed W, Noga SJ, Gee AP, Rooney CM, Wagner JE, McCullough J, McKenna DH, Whiteside TL, Donnenberg AD, Baker AK, Linblad RW, Wagner EL, Mondoro TH,. Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies. Transfusion 2009; 49: 786-96.